1	Cross-cultural translation and psychometric validation of the
2	French version of the Fear-Avoidance Components Scale (FACS)
3	Arnaud Duport <sup>1,2</sup> , Sonia Bédard <sup>3-4</sup> , Catherine Raynauld <sup>3-4</sup> , Martine Bordeleau <sup>2</sup> , Randy Neblett <sup>5</sup> ,
4	Frédéric Balg <sup>3-4</sup> , Hervé Devanne <sup>1</sup> , Guillaume Léonard <sup>2,3*</sup>
5	<sup>1</sup> Univ. Littoral Côte d'Opale, Univ. Artois, Univ. Lille, ULR 7369 - URePSSS - Unité de Recherche
6	Pluridisciplinaire Sport Santé Société, F-62100 Calais, France
7	<sup>2</sup> Research Center on Aging, CIUSSS de l'Estrie-CHUS, 1036 rue Belvédère Sud, Sherbrooke, Qc J1H
8	4C4, Canada
9	<sup>3</sup> Centre de recherche du CHUS, École de réadaptation, Faculté de médecine et des sciences de la santé,
10	Université de Sherbrooke 3001, 12e Avenue Nord, Sherbrooke, Qc, Canada, J1H 5N4
11	<sup>4</sup> Surgery department, Orthopedic service, Université de Sherbrooke, Qc, Canada
12	<sup>5</sup> PRIDE Research Foundation, Dallas, TX, USA
13	*Correspondence:
14	Guillaume Léonard
15	guillaume.leonard2@usherbrooke.ca
16	Keywords: Fear avoidance, Fear-avoidance Components Scale, French version, Canadian
17	French version, kinesiophobia, behavioral medicine, psychometrics

## 18 **1** Abstract

Background: The Fear-Avoidance Components Scale (FACS) is a reliable and valid instrument widely used to assess fear-avoidance beliefs related to pain and disability. However, there is a scarcity of validated translations of the FACS in different cultural and linguistic contexts, including the French population. This study aimed to translate and validate the French version of the FACS (FACS-Fr/CF), examining its psychometric properties among French-speaking individuals.

Methods: A cross-cultural translation process – including forward translation, backward translation, expert committee review, and pre-testing – was conducted to develop the FACS-Fr/CF. The translated version was administered to a sample of French-speaking adults (n=55) with musculoskeletal conditions. Internal consistency (including confirmatory analyses of the 2 factors identified in the Serbian version), test-retest reliability and convergent validity were then assessed.

**Results:** The FACS-Fr/CF demonstrated high global internal consistency ( $\alpha$ =0.94, 95% CI: 0.91-0.96) as well as high internal consistency of the 2 factors identified in the Serbian version ( $\alpha$ =0.90, 95% CI: 0.86-0.94 and  $\alpha$ =0.90, 95% CI: 0.85-0.94, respectively). Test-retest analysis revealed a moderate (close to high) reliability (ICC=0.89; 95% CI: 0.82-0.94 and r=0.89; *p*<0.005). Convergent validity was supported by significant correlations between the FACS-Fr/CF scores and the Tampa Scale for Kinesiophobia (r=0.82; *p* < 0.005), the Pain Catastrophizing Scale (r=0.72; *p* < 0.005) and the Hospital Anxiety and Depression Scale (r=0.66; *p* < 0.005).

Conclusion: The present study provides evidence for the cross-cultural translation and psychometric
 validation of the FACS-Fr/CF. The FACS-Fr/CF exhibits a high internal consistency, a moderate (close
 to high) test-retest reliability, and good construct validity, suggesting its utility in assessing fear-

- 39 avoidance beliefs in the French-speaking population. This validated tool can enhance the assessment
- 40 and understanding of fear-avoidance behaviors and facilitate cross-cultural research in pain-related
- 41 studies.

42

## 43 **2** Introduction

The fear-avoidance (FA) model is proposed as a possible explanation for the transition from acute to chronic pain in some patients [1,2]. According to this model, individuals who perceive their pain as threatening and who catastrophize will tend to develop fear of pain, avoid regular activities, and monitor excessively bodily sensations [1,3,4]. These responses may precipitate physical deconditioning, limit the ability to work and to participate in recreational/familial activities, and foster depression [1,3,4].

50 Several patient-reported outcome (PRO) questionnaires have been developed to quantify FA related 51 concepts, including the Tampa Scale for Kinesiophobia (TSK) [5], the Pain Anxiety Symptoms Scale 52 (PASS) [6], the Pain Catastrophizing Scale (PCS) [7], and the Fear-Avoidance Beliefs Questionnaire 53 (FABO) [8]. However, the FA model has significantly evolved in recent years, and none of these 54 questionnaires comprehensively examine all the cognitive, emotional, and behavioral components of 55 the model [9]. Although they have been used in a substantial number of peer-reviewed published 56 research, the psychometric properties of these tools (including construct validity and sensitivity to 57 change) have sometimes been called into question [10], and some of their items have received criticism 58 for being either too narrowly defined (only applicable to a single situation) or overly broad (too vague 59 or subject to interpretation) [11]. Furthermore, while pain-related avoidance can occur due to fear of 60 injury or reinjury, fear of increased pain, or an actual increase in pain, none of these questionnaires 61 attempt to distinguish between these different cases [12].

62 In an attempt to address these shortcomings, Neblett et al. (2015) have developed the Fear Avoidance 63 Component Scale (FACS) [9], which includes items from other published FA related measures (TSK, 64 PASS, PCS, FABO). The FACS also includes items based on the Injustice Experience Questionnaire 65 (IEQ) [13], designed to assess the degree to which chronic pain sufferers feel injustice in relation to 66 their pain. All FACS items were created to assess specific fear avoidance related beliefs and feelings about a person's painful medical condition, such as cognitive (pain catastrophizing), affective (pain-67 related fear and anxiety), and behavioral (avoidance) constructs [9]. In addition, six items (15 to 20) 68 69 were developed to assess the specific types of activities and physical intensity of activities (from low 70 to strenuous) that an individual avoids, and three items were developed to evaluate why the individual 71 is avoiding these activities [9].

72 The original English version of the FACS has shown acceptable test-retest reliability (r=0.90-0.94) as 73 well as acceptable internal consistency (Cronbach  $\alpha$ =0.92) [9]. The FACS has been translated and 74 validated in several different languages. It has shown good psychometric properties in Serbian (test-75 retest reliability: ICC = 0.93; internal consistency: Cronbach  $\alpha$  =0.90) [14], Spanish (convergent 76 validity: r=0.41; internal consistency: Cronbach  $\alpha$ =0.90-0.88) [15], Gujarati (test-retest reliability: 77 ICC=0.92; internal consistency: Cronbach  $\alpha$ =0.83) [16], Dutch (internal consistency: Cronbach 78  $\alpha$ =0.92; test-retest reliability: ICC=0.92, CI 0.80-0.96) [17] and Turkish (internal consistency: 79 Cronbach  $\alpha$ =0.815; test-retest reliability: ICC=0.53-0.97).

There are currently about 321 million French speakers throughout the world. [18] However, a psychometrically validated French version of the FACS has not been made available to date. Clinical settings in French-speaking parts of the world – including France and Canada – could certainly benefit from a French version of this questionnaire. The aim of the current study was to translate the FACS

into a common French version, including dialects of France and Canadian French (FACS-Fr/CF), and
 to assess the psychometric properties of the translated questionnaire – including internal consistency,
 test-retest reliability, and construct validity.

## 87 **3** Materials and Methods

The study was approved by the ethics committee of the Research Center on Aging du Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie CHUS) and registered on the ClinicalTrials website (NCT05217017). This study was conducted according to the principles expressed in the Declaration of Helsinki [19].

#### 92 **3.1 Cross-cultural translation process**

93 The translation was performed using a six-step process according to the guidelines for the cross-cultural 94 adaptation process written by the American Association of Orthopaedic Surgeons [20]. Initial 95 translation, synthesis, back translation, expert committee, test of the prefinal version and submission 96 of the document to the one of the original developers (RN) were performed. For the initial translation, 97 two independent translators (ST and SW), whose mother tongue was French, translated the scale from 98 English to French. A synthesized version of the two translated questionnaires was completed after 99 discussion with the translator and research team. Two independent translators (BVD and AS), blinded 100 to the original scale and whose native language was English, then translated the synthesized version 101 back to English. An expert committee, comprised of the four translators and the research team, 102 consolidated the prefinal version.

103 The content validity of the French FACS was pre-tested by 10 healthcare professionals (including 104 physiotherapists, nurses, neuropsychiatrists, and orthopedic surgeons) and 20 individuals (healthy and 105 pain patients), including 10 in Quebec (Canada), and 10 in France. All of them tested the prefinal 106 version by completing the questionnaire and evaluating their understanding of each item. Each person 107 was invited to report any interpretation difficulties and other observations about each test item [20]. 108 Based on participants' answers, only item 13 « La douleur causée par mon état de santé est un signal 109 d'alerte indiquant que quelque chose ne va pas du tout chez moi» ("The pain from my medical 110 condition is a warning signal that something is dangerously wrong with me") turned into « La douleur 111 causée par mon état de santé est un signal d'alerte indiquant que quelque chose ne va pas du tout » 112 ("The pain from my medical condition is a warning signal that something is dangerously wrong"). This 113 modification was made because of the end of the sentence (« *chez moi* »), suggesting a psychiatric 114 disorder connotation in French. For the final step, the methods for obtaining the corrected French 115 version (FACS-Fr/CF) were submitted to author (RN), one of the developers of the original FACS 116 questionnaire (Fig 1). The cross-cultural translation process period ran from March 14, 2022 to March 117 31, 2022.

118

#### 119 Fig 1. Flowchart of the development of the FACS-Fr/CF

120

## 121 **3.2** Psychometric evaluation of the FACS-Fr/CF

After cross-cultural adaptation and translation, the final version of the FACS-Fr/CF questionnaire was administered to a sample of participants suffering from chronic pain to evaluate internal consistency,

124 test-retest reliability, and convergent validity. This validation step was performed according to 125 specialized pain medicine guidelines [21].

#### 126 **3.2.1 Study population**

127 The target population for this study included patients with chronic musculoskeletal pain who spoke

128 French as their first language and referred by a physician for a musculoskeletal condition at the hospital

129 CIUSSS de l'Estrie-CHUS (convenience sampling method). The eligibility criteria were: 1) 18 years

130 of age or older; 2) French as first language; and 3) chronic musculoskeletal pain for at least 3 months.

131 Subjects were excluded if they were unable to consent, read or understand the study requirements (see

132 Fig 2). The inclusion period ran from April 26, 2022 to November 1, 2022.

133

#### 134 Fig 2. Patient recruitment flowchart

135

#### 136 **3.2.2 Sample size**

To follow the Consensus-based Standards for the Selection of Health Measurement Instruments recommendations, we recruited 55 participants to meet the objectives of this study (50+10% loss) for the assessment of internal consistency, reliability and validity [22]. This percentage of loss to followup was based on the latest research at the CHUS orthopedic service and on a systematic review focused on orthopedic clinical services [23].

#### 142 **3.2.3 Patient-reported outcome measures**

143 The Fear-Avoidance Components Scale (FACS) is a self-reported questionnaire used to 144 comprehensively measure and identify FA in patients with painful medical conditions [24]. It brings 145 together major FA components from earlier FA scales while seeking to address some of their 146 inadequacies within the context of the most recent FA model [11]. This questionnaire consists of 20 147 items on a Likert scale, ranging from 5 (completely agree) to 0 (completely disagree). The total score, 148 which varies from 0 to 100, is calculated by adding the values of each item. The FACS includes 5 149 severity levels with increasing severity, based upon quintiles: Subclinical (0 to 20), Mild (21 to 40), 150 Moderate (41 to 60), Severe (61 to 80), and Extreme (81 to 100). Psychometric properties of the FACS 151 show high internal consistency ( $\alpha = 0.92$ ) and high test-retest reliability (r = 0.90-0.94, P < 0.01) [24]. 152 The Serbian version of FACS found 2 different factors; factor 1 dealt with "general fear avoidance" 153 and included items 1-14, while factor 2 was related to "types of activities that are avoided" and included 154 items 15-20) [14].

The Tampa Scale for Kinesiophobia - Canadian French version (TSK-CF) is a self-reported questionnaire used to assess kinesiophobia. The TSK-CF has demonstrated good psychometric properties (Cronbach's alpha = 0.71 and ICC > 0.7) [25,26]. This questionnaire consists of 17-items evaluated on a Likert scale, ranging from 1 (strongly disagree) to 4 (strongly agree). The total score, which varies from 17 to 68, is calculated by adding the values of each item. There is no specific threshold to indicate a clinically disabling level of kinesiophobia [27].

161 The Pain Catastrophizing Scale - Canadian French version (PCS-CF) is a self-reported questionnaire 162 used to measure catastrophic thoughts. The PCS-CF has shown good psychometric properties 163 (Cronbach's alpha = 0.87 and ICC > 0.7) [28–31]. This questionnaire consists of 13 items, rated on a

Likert scale from 0 (not at all) to 4 (always), that can be categorized into three subscales: rumination (being unable to stop thinking about how much it hurts), amplification (exaggerating the threat value of pain sensations), and feelings of helplessness (feeling unable to cope with pain) [32]. The sum of the 13 items' values yields the final score, which ranges from 0 to 52. It has been suggested that a threshold score of 30 or higher can be used to identify people who have a clinically significant level of pain catastrophizing [33].

The Hospital Anxiety and Depression Scale - French Canadian version (HADS-FC) is a self-reported questionnaire used to measure the symptoms of anxiety and depression [34]. This questionnaire consists of 14 items intended to evaluate the severity of anxiety and depressive symptoms on two different subscales using a 4-point Likert-type scale (ranging between 0 and 3). Higher scores on the total scale indicate greater psychological distress. The internal consistency of the French version is good [35], with the depression subscale having Cronbach's alpha of 0.78 and the anxiety subscale having a Cronbach's alpha of 0.81.

177 **3.2.4 Study process and procedures** 

Participants were recruited during an initial medical consultation visit at the orthopedic clinic of the CIUSSS de l'Estrie – CHUS. After the orthopedist completed the examination and consent to participate was obtained, patients were asked to complete a short sociodemographic questionnaire (including sex, age, physician's diagnosis, pain duration and academic level) using an online REDCap platform (REDCap 12.4.2 - © 2023 Vanderbilt University) [36]. Patients were then asked to fill out the four questionnaires (FACS-Fr/CF, TSK-CF, PCS-CF, HADS-CF). The questionnaires were completed online (REDCap) or on paper, depending on the participants' convenience or preference.

185	Then, seven days later, the patients were asked to complete the FACS-Fr/CF a second time, in the same
186	way as the first time (online or paper). This timeframe was short enough to avoid significant clinical
187	fluctuations from first completion and allow an appropriate test-retest evaluation [37].

#### 188 **3.2.5 Statistical analysis**

- 189 Cronbach's alpha was used to assess the global internal consistency of the FACS-Fr/CF. We performed
- a global and confirmatory factors analysis (1 and 2) of the Serbian version. According to Wind *et al.*,
- 191 2005,  $\alpha \ge 0.80$ ,  $\alpha \ge 0.70$  and  $\alpha < 0.70$  are considered as high, moderate and low, respectively [38].
- 192 The reliability was calculated with test-retest intraclass correlation coefficients (ICC) and Pearson
- 193 correlation coefficients. According to Wind *et al.*, 2005, ICC  $\ge$  0.90, ICC  $\ge$  0.75 and ICC < 0.75 are
- 194 considered as high, moderate and low, respectively [38].
- 195 Convergent validity was assessed using Pearson's correlation coefficients, comparing the FACS-Fr/CF
- 196 with the TSK-CF, the PCS-CF, and the HADS-FC. According to Wind *et al.*, 2005,  $r \ge 0.60$ ,  $r \ge 0.30$
- and r < 0.30 are considered as high, moderate and low, respectively [38]. Considering the constructs
- 198 of these different questionnaires, we expected to find stronger correlations with TSK-CF, followed by
- 199 the PCF-CF and the HADS-FC.
- All statistical analyses were performed using  $SPSS^{\mathbb{R}}$  (version 21); the significance level set at p=0.05.

## 201 **4 Results and discussion**

## 202 4.1 Participants' characteristics

203	Demographic information is provided in Table 1. Fifty-five (55) participants took part in the study,
204	including 30 men (54.5%) and 25 women (45.5%). The average age for the total sample was
205	51.15±16.47 years old. The average pain duration was 65.67±86.80 months. Pain-related medical
206	diagnoses included arthrosis (n=12), tendinopathy (n=9), coxalgia (n=8), ligamentoplasty (n=6),
207	labrum tear (n=5), tendon rupture (n=3), and low back pain (n=2). One subject each, for the remaining
208	10 patients, were diagnosed with the following: stenosing flexor tenosynovitis, femur elongation,
209	cervical surgery, elbow fracture, ankle pain, complex regional pain syndrome (CRPS), neuropathy of
210	upper limbs, patellofemoral syndrome, Baker's cyst, crowned dens syndrome. The study ended on
211	November 11, 2022 with the receipt of the last questionnaire.

212	Table 1.	Participant	characteristics
-----	----------	-------------	-----------------

Participant's characteristics	Total sample or				
	mean (% or SD)				
Age (years)	51.15 (16.47)				
Sex	30 men (54.5%)				
	25 women (45.5%)				
Diagnosis	Arthrosis (12)				
	Tendinopathy (9)				
	Coxalgia (8)				
	Ligamentoplasty (6)				
	Labrum tear (5)				
	Tendon rupture (3)				
	Low back pain (2)				
	Other (10)				
Pain duration (months)	65.67 (86.80)				
FACS-Fr/CF (at first time)	47.35 (22.85)				
PCF-CF	19.40 (13.81)				
TSK-CF	40.94 (9.71)				
HADS-FC	13.49 (8.06)				
FACS-Fr/CF (retest 7 days later)	45.43 (21.84)				

213

## 214 **4.2 Internal consistency**

- 215 The global internal consistency of FACS-Fr/CF calculated by Cronbach's alpha was high ( $\alpha$ =0.94,
- 216 95% CI: 0.91-0.96). For factors 1 and 2, the Cronbach's alpha was high for both ( $\alpha$ =0.90, 95% CI:
- 217 0.86-0.94 and  $\alpha$ =0.90, 95% CI: 0.85-0.94 respectively). The descriptive statistics and internal
- 218 consistency for the FACS-Fr/CF items are shown in Table 2.

#### 219 Table 2. Internal consistency for the FACS-Fr/CF items

FACS-Fr/CF items	Corrected total-item correlation	Cronbach's alpha if item deleted		
1	.475	.934		
2	.519	.934		
3	.643	.931		
4	.693	.930		
5	.677	.931		
6	.451	.935		
7	.641	.931		
8	.740	.930		
9	.708	.930		
10	.641	.931		
11	.727	.930		
12	.299	.938		
13	.516	.934		
14	.617	.932		
15	.634	.932		
16	.722	.930		
17	.617	.932		
18	.826	.928		
19	.695	.930		
20	.652	.931		

220

## 221 4.3 Reliability test retest

- 222 Test-retest reliability of the FACS-Fr/CF was moderate, close to high (ICC=0.89; 95% CI: 0.82-0.94
- and r=0.89; *p*<0.005) [39].

## 224 **4.4 Convergent validity**

- 225 The convergent validity was assessed with Pearson's correlation coefficients (unilateral). The FACS-
- 226 Fr/CF scores were highly correlated with scores on the TSK-CF (r=0.82; p < 0.005), PCS-CF (r=0.72;
- p < 0.005) and HADS-FC (r=0.66; p < 0.005). All correlation coefficients are shown in Table 3.

#### 228 Table 3. Pearson's correlations (2-tailed) among PROs

	FACS-Fr/CF	PCS-CF	TSK-CF	HADS-FC
FACS-Fr/CF	-			
PCS-CF	0.72***	-		
TSK-CF	0.82***	0.61***	-	
HADS-FC	0.66***	0.69***	0.66***	-

<sup>\*\*\*</sup> means p<0.005

## 230 4.5 Discussion

This study aimed to establish and validate a cross cultural adaptation of the FACS questionnaire in French and Canadian French, using the guidelines for questionnaires in pain medicine proposed by Tsang, Royse and Terkawi [21]. Following a forward and backward translation process, and feedback from 10 healthcare professionals and 20 patients, a final version of the FACS-Fr/CF was established. The psychometric properties were then assessed in a sample of 55 chronic pain patients who completed the final FACS-Fr/CF on 2 occasions at a 2-week interval, as well as 3 other questionnaires, which assessed related constructs.

Global internal consistency of FACS-Fr/CF was high ( $\alpha$ =0.94,) and comparable to the original FACS ( $\alpha$ =0.92) [24]. The internal consistency of the 2 factors identified previously in the Serbian version was also high, despite the relatively small number of items for factor 2. Test-retest reliability of the FACS-Fr/CF was moderate, very close to high. These values are consistent with those obtained for the original version (r = 0.90-0.94, P < 0.01) [24].

243 For convergent validity, we assessed the relationship between the scores of the FACS-Fr/CF, the TSK-244 CF, the PCS-CF and the HADS-FC. A previous study with the Spanish and Turkish versions of the 245 FACS found a moderate and strong correlation with the Spanish and Turkish version of the TSK, with 246 a coefficient r=0.39 and r=0.56 respectively [40,41]. In the present study, we observed a high 247 correlation between the FACS-Fr/CF and the TSK-CF (r=0.82). As expected, the correlation was 248 higher with the TSK-CF, compared to the PCS-CF (r=0.72) and the HADS-FC (r=0.66), suggesting 249 that the constructs underlying the FACS and TSK are particularly close [24]. This finding is perhaps 250 not so surprising when we bear in mind that some of the items from the FACS were borrowed directly 251 from the TSK [9].

We also examined the convergent validity of FACS, by assessing its relationship with the PCS. In previous studies, the Spanish version showed a moderate correlation with the PCS (r=0.49 to 0.53) [40,42], and the Serbian and Turkish versions showed a high correlation (r=0.77 and r=0.68 respectively) [14,41]. The high correlation between the FACS-Fr/CF and PCS-CF (r=0.72; p < 0.005) was very close to the Serbian and Turkish versions.

FA is frequently associated with anxiety [43] and depression [44]. Though anxiety and depression are related to FA, these constructs are somewhat different [45]. The association between FACS-Fr/CF and

HADS-FC scores was therefore expected to be weaker than those observed between the FACS-Fr/CF
and TSK-CF, and between the FACS-Fr-CF and PCS-CF.

All in all, the pattern of convergent validity results in the present study is consistent with the a priori assumptions that postulated a higher correlation coefficient between FACS-Fr/CF and TSK-CF scores [46,47], followed by the PCS-CF (with symptoms of helplessness, rumination and magnification being an important component of the FA model [48]) and by the HADS-FC [49].

265 This study has a number of strengths and limitations. One strength was that the American Association 266 of Orthopedic Surgeons and the Consensus-based Standards for the Selection of Health Measurement 267 Instruments recommendations were followed in the cross-cultural adaptation and validation process. 268 Furthermore, the FACS-Fr/CF was developed as a standardized version, accommodating two distinct 269 French language dialects (France and Canada). As a result, it has potential for broad applicability across 270 diverse French-speaking regions, worldwide. However, it is important to exercise caution when using 271 the instrument in specific contexts, as further validation studies may be necessary to ensure its 272 appropriateness for local linguistic variations and cultural nuances.

An important limitation of this study concerns recruitment, as the 55 patients included in the sample were recruited from a single hospital – a situation that may raise questions about the generalizability of the results. However, it is important to note that this limitation may be partially mitigated by the important variability observed among the pain conditions encompassed within the sample. Nonetheless, extrapolating the results to broader chronic pain populations, outside the specific context of the study, should be done with caution.

279

## 280 5 Conclusions

This is the first translation, intercultural adaptation and validation study of the FACS in French version, including dialects of France and Canadian French. The FACS-Fr/CF showed a high global internal consistency and moderate (very close to high) test-retest reliability. The convergent validity of the FACS-Fr/CF was demonstrated by positive correlations with TSK, PCS and HADS. This work provides an important basis for the future use of the FACS-Fr/CF in assessing fear-avoidance beliefs in various French-speaking cultural contexts.

## 287 6 Supporting information

288 S1 File. Fear-avoidance Components Scale, French/Canadian French version (FACS-Fr/CF)

289

## 290 7 Conflict of Interest

291 The authors declare that the research was conducted in the absence of any commercial or financial 292 relationships that could be construed as a potential conflict of interest.

## 293 8 Funding

294 This study was funded by Fond de Recherche et Enseignement en Orthopédie de Sherbrooke (FREOS).

295 GL received salary support by the Fonds de recherche du Québec – Santé (FRQS).

## 296 9 Acknowledgments

We would especially like to thank Doctor Stéphane Ricard and the orthopedic service of CIUSSS de l'Estrie-CHUS for recruiting participants, as well as Professor Cynthia Gagnon for her help with the translation process.

## 300 10 References

- Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain:
   a state of the art. Pain. 2000/04/27 ed. 2000;85: 317–332. doi:10.1016/s0304-3959(99)00242-0
- 303 2. Lethem J, Slade PD, Troup JD, Bentley G. Outline of a Fear-Avoidance Model of exaggerated
- 304 pain perception--I. Behav Res Ther. 1983;21: 401–408. doi:10.1016/0005-7967(83)90009-8
- Vlaeyen JWS, Kole-Snijders AMJ, Rotteveel AM, Ruesink R, Heuts PHTG. The role of fear of
   movement/(re)injury in pain disability. J Occup Rehab. 1995;5: 235–252.
   doi:10.1007/BF02109988
- Vlaeyen JW, Linton SJ. Fear-avoidance model of chronic musculoskeletal pain: 12 years on. Pain.
   2012;153: 1144–1147.
- Miller RP, Kori SH, Todd DD. The Tampa Scale: a measure of kinisophobia. The Clinical journal
  of pain. 1991;7: 51.
- McCracken LM, Zayfert C, Gross RT. The Pain Anxiety Symptoms Scale: development and
  validation of a scale to measure fear of pain. Pain. 1992;50: 67–73. doi:10.1016/03043959(92)90113-P

315	7.	Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation.

- 316
   Psychological Assessment. 1995;7: 524–532. doi:10.1037//1040-3590.7.4.524
- Waddell G, Newton M, Henderson I, Somerville D, Main CJ. A Fear-Avoidance Beliefs
   Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and
   disability. Pain. 1993;52: 157–168. doi:10.1016/0304-3959(93)90127-B
- 320 9. Neblett R, Mayer TG, Hartzell MM, Williams MJ, Gatchel RJ. The Fear-avoidance Components
- 321 Scale (FACS): Development and Psychometric Evaluation of a New Measure of Pain-related Fear
- 322 Avoidance. Pain Pract. 2015;16: 435–450. doi:10.1111/papr.12333
- Lundberg M, Grimby-Ekman A, Verbunt J, Simmonds MJ. Pain-related fear: a critical review of
  the related measures. Pain Res Treat. 2011;2011: 494196. doi:10.1155/2011/494196
- Pincus T, Smeets RJEM, Simmonds MJ, Sullivan MJL. The fear avoidance model disentangled:
  Improving the clinical utility of the fear avoidance model. Clin J Pain. 2010;26: 739–746.
  doi:10.1097/AJP.0b013e3181f15d45
- Rainville J, Smeets RJEM, Bendix T, Tveito TH, Poiraudeau S, Indahl AJ. Fear-avoidance beliefs
  and pain avoidance in low back pain--translating research into clinical practice. Spine J. 2011;11:
  895–903. doi:10.1016/j.spinee.2011.08.006

331 13. Sullivan MJ, Adams H, Horan S, Maher D, Boland D, Gross R. The role of perceived injustice in
the experience of chronic pain and disability: scale development and validation. J Occup Rehabil.
2008/06/10 ed. 2008;18: 249–61. doi:10.1007/s10926-008-9140-5

334	14.	Knezevic A, Neblett R, Gatchel RJ, Jeremic-Knezevic M, Bugarski-Ignjatovic V, Tomasevic-						
335		Todorovic S, et al. Psychometric validation of the Serbian version of the Fear Avoidance						
336		Component Scale (FACS). PLoS One. 2018;13: e0204311. doi:10.1371/journal.pone.0204311						
337	15.	Cuesta-Vargas AI, Neblett R, Gatchel RJ, Roldán-Jiménez C. Cross-cultural adaptation and						
338		validity of the Spanish fear-avoidance components scale and clinical implications in primary care.						
339		BMC Fam Pract. 2020;21: 44. doi:10.1186/s12875-020-01116-x						
340	16.	Bid DD, Neblett R, Alagappan TR, Patel CJ, Patel KN, Patel RL, et al. Cross-cultural adaptation,						
341		reliability, and validity of the Gujarati fear-avoidance components scale. Physiotherapy-The						
342		Journal of Indian Association of Physiotherapists. 2020;14: 98.						
343	17.	De Baets L, Sergooris A, Neblett R, Matheve T, Mingels S, Van Goethem A, et al. The						
344		development and measurement properties of the Dutch version of the fear-avoidance components						
345		scale (FACS-D) in persons with chronic musculoskeletal pain. Scand J Pain. 2022.						
346		doi:10.1515/sjpain-2022-0046						
347	18.	Organisation internationale de la Francophonie. La langue française dans le monde, Synthèse						
348		2022.Consultedon :2022-10-07.Availableat:						
349		https://www.francophonie.org/sites/default/files/2022-						
350		03/Synthese_La_langue_francaise_dans_le_monde_2022.pdf. Gallimard. 2022.						
351	19.	WMA - The World Medical Association-Déclaration d'Helsinki de L'AMM – Principes éthiques						
352		applicables à la recherche médicale impliquant des êtres humains. [cited 24 Nov 2020]. Available:						
353		https://www.wma.net/fr/policies-post/declaration-dhelsinki-de-lamm-principes-ethiques-						
354		applicables-a-la-recherche-medicale-impliquant-des-etres-humains/						
		20						

- Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural
  adaptation of self-report measures. Spine (Phila Pa 1976). 2000;25: 3186–3191.
  doi:10.1097/00007632-200012150-00014
- 358 21. Tsang S, Royse CF, Terkawi AS. Guidelines for developing, translating, and validating a
  questionnaire in perioperative and pain medicine. Saudi J Anaesth. 2017;11: S80–S89.
  doi:10.4103/sja.SJA 203 17
- 361 22. Mokkink LB, de Vet HCW, Prinsen C a. C, Patrick DL, Alonso J, Bouter LM, et al. COSMIN
  362 Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. Qual Life
  363 Res. 2018;27: 1171–1179. doi:10.1007/s11136-017-1765-4
- 364 23. Somerson JS, Bartush KC, Shroff JB, Bhandari M, Zelle BA. Loss to follow-up in orthopaedic
  365 clinical trials: a systematic review. Int Orthop. 2016;40: 2213–2219. doi:10.1007/s00264-016366 3212-5
- 367 24. Neblett R, Mayer TG, Hartzell MM, Williams MJ, Gatchel RJ. The Fear-avoidance Components
   368 Scale (FACS): Development and Psychometric Evaluation of a New Measure of Pain-related Fear
   369 Avoidance. Pain Pract. 2016;16: 435–450. doi:10.1111/papr.12333

French DJ, Roach PJ, Mayes S. Peur du mouvement chez des accidentés du travail: L'Échelle de
Kinésiophobie de Tampa (EKT). [Fear of movement in injured workers: The Tampa Scale of
Kinesiophobia.]. Canadian Journal of Behavioural Science / Revue canadienne des sciences du
comportement. 2002;34: 28–33. doi:10.1037/h0087152

Weermeijer JD, Meulders A. Clinimetrics: Tampa Scale for Kinesiophobia. Journal of
Physiotherapy. 2018;64: 126. doi:10.1016/j.jphys.2018.01.001

376	27.	Vlaeyen JW, Kole-Snijders AM, Boeren RG, van Eek H. Fear of movement/(re)injury in chronic
377		low back pain and its relation to behavioral performance. Pain. 1995;62: 363-372.
378	28.	French DJ, Noël M, Vigneau F, French JA, Cyr CP, Evans RT. L'Échelle de dramatisation face
379		à la douleur PCS-CF: Adaptation canadienne en langue française de l'échelle «Pain
380		Catastrophizing Scale». [PCS-CF: A French-language, French-Canadian adaptation of the Pain
381		Catastrophizing Scale.]. Canadian Journal of Behavioural Science / Revue canadienne des
382		sciences du comportement. 2005;37: 181-192. doi:10.1037/h0087255
383	29.	Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O'Neill E. Factor structure, reliability,
384		and validity of the Pain Catastrophizing Scale. Journal of Behavioral Medicine. 1997;20: 589-
385		605. doi:10.1023/A:1025570508954
386	30.	Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation.
387		Psychological Assessment. 1995;7: 524-532. doi:10.1037//1040-3590.7.4.524
388	31.	Tremblay I, Beaulieu Y, Bernier A, Crombez G, Laliberté S, Thibault P, et al. Pain
389		Catastrophizing Scale for Francophone Adolescents: a preliminary validation. Pain Res Manag.
390		2008;13: 19–24.
391	32.	Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain
392		Catastrophizing Scale: further psychometric evaluation with adult samples. J Behav Med.
393		2000;23: 351–365.

394 33. Sullivan MJ. The Pain Catastrophizing Scale. 2009; 36.

395	34.	Rober	ge P, Do	ré I, N	Menear M, C	hartrand	É, C	Ciampi A, I	Duhoux A,	et al. A psy	chometric
396		evalua	tion of th	e Fren	ich Canadian	version c	of the	e Hospital	Anxiety and	Depression	Scale in a
397		large	primary	care	population.	Journal	of	Affective	Disorders.	2013;147:	171–179.
398		doi:10	).1016/j.ja	d.2012	.10.029						


- 399 35. Bocéréan C, Dupret E. A validation study of the Hospital Anxiety and Depression Scale (HADS)
  400 in a large sample of French employees. BMC Psychiatry. 2014;14: 354. doi:10.1186/s12888-014401 0354-0
- 402 36. Garcia KKS, Abrahão AA. Research Development Using REDCap Software. Healthc Inform
  403 Res. 2021;27: 341–349. doi:10.4258/hir.2021.27.4.341
- 404 37. Streiner DL, Norman GR, Cairney J. Health measurement scales: A practical guide to their
  405 development and use, 5th ed. New York, NY, US: Oxford University Press; 2015. pp. xiii, 399.
  406 doi:10.1093/med/9780199685219.001.0001
- 407 38. Wind H, Gouttebarge V, Kuijer PPFM, Frings-Dresen MHW. Assessment of functional capacity
- 408 of the musculoskeletal system in the context of work, daily living, and sport: a systematic review.
- 409 J Occup Rehabil. 2005;15: 253–272. doi:10.1007/s10926-005-1223-y
- 410 39. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for
  411 Reliability Research. J Chiropr Med. 2016;15: 155–163. doi:10.1016/j.jcm.2016.02.012
- 412 40. Gutiérrez-Sánchez D, Roldán-Jiménez C, Pajares B, Alba E, Cuesta-Vargas AI. Validity and
- 413 reliability of the Spanish fear-avoidance components scale in breast cancer survivors. European
- 414 Journal of Cancer Care. 2021;30: e13506. doi:10.1111/ecc.13506

- 41. Turan K, Sarı Z, Özden F. Psychometric properties of the Turkish version of the fear avoidance
  components scale in patients with chronic pain related to musculoskeletal disorders. Wien Klin
  Wochenschr. 2023. doi:10.1007/s00508-023-02224-1
- 418 42. Pérez-Cruzado D, Roldan-Jimenez C, Iglesias-Campos M, Pajares B, Alba E, Cuesta-Vargas A.
  419 Validation of pain catastrophizing scale on breast cancer survivor. Pain Pract. 2022;22: 711–717.
  420 doi:10.1111/papr.13163
- 43. Pincus T, Vogel S, Burton AK, Santos R, Field AP. Fear avoidance and prognosis in back pain:
  a systematic review and synthesis of current evidence. Arthritis Rheum. 2006;54: 3999–4010.
  doi:10.1002/art.22273
- 424 44. Brindisino F, Garzonio F, DI Giacomo G, Pellegrino R, Olds M, Ristori D. Depression, fear of
  425 re-injury and kinesiophobia resulted in worse pain, quality of life, function, and level of return to
  426 sport in patients with shoulder instability. A systematic review. J Sports Med Phys Fitness. 2022.
  427 doi:10.23736/S0022-4707.22.14319-7
- 428 45. Sloan E, Hall K, Moulding R, Bryce S, Mildred H, Staiger PK. Emotion regulation as a
  429 transdiagnostic treatment construct across anxiety, depression, substance, eating and borderline
  430 personality disorders: A systematic review. Clin Psychol Rev. 2017;57: 141–163.
  431 doi:10.1016/j.cpr.2017.09.002
- 432 46. Abma IL, Rovers M, van der Wees PJ. Appraising convergent validity of patient-reported
  433 outcome measures in systematic reviews: constructing hypotheses and interpreting outcomes.
  434 BMC Res Notes. 2016;9: 226. doi:10.1186/s13104-016-2034-2

435	47.	French DJ, France CR,	Vigneau F,	French JA,	Evans RT. Fe	ear of movement	/(re)injury	in chronic
-----	-----	-----------------------	------------	------------	--------------	-----------------	-------------	------------


- 436 pain: a psychometric assessment of the original English version of the Tampa scale for
- 437 kinesiophobia (TSK). Pain. 2007;127: 42–51. doi:10.1016/j.pain.2006.07.016
- 438 48. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation.
- 439 Psychological Assessment. 1995;7: 524–532. doi:10.1037//1040-3590.7.4.524
- 440 49. Djukanovic I, Carlsson J, Årestedt K. Is the Hospital Anxiety and Depression Scale (HADS) a
- 441 valid measure in a general population 65–80 years old? A psychometric evaluation study. Health
- 442 Qual Life Outcomes. 2017;15: 193. doi:10.1186/s12955-017-0759-9

443



# Fig1

# Total number of patients invited to take part (n=58)



# Fig2